In the 10 DKA cases of T2DM patients who were using SGLT2 inhibitors, 6 had concomitant infections, 1 had insulin omission, and there were no other concomitant risks in 3 patients. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.